The effects of age and liver disease on the disposition and elimination of diazepam in adult man.

Cholangiography in the jaundiced patient. Gut (1976) 2.44

Clinical pharmacology and therapeutics of benzodiazepines. Can Med Assoc J (1978) 2.40

Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol (1977) 1.90

Increased sensitivity to nitrazepam in old age. Br Med J (1977) 1.79

Pharmacokinetics and metabolism of various benzodiazepines used as hypnotics. Br J Clin Pharmacol (1979) 1.75

Drugs and the elderly. Ann Rheum Dis (1990) 1.66

Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program. Br J Clin Pharmacol (1978) 1.65

Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmacol (1981) 1.59

Diazepam and 3-hydroxydiazepam (temazepam) and sleep of middle age. Br J Clin Pharmacol (1979) 1.57

The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol (2008) 1.56

Sedation for fibreoptic bronchoscopy. Thorax (1989) 1.35

Enhanced drug metabolism in cigarette smokers. Br Med J (1976) 1.31

Prazosin disposition in young and elderly subjects. Br J Clin Pharmacol (1981) 1.24

The effects of age and smoking on the plasma protein binding of lignocaine and diazepam. Br J Clin Pharmacol (1985) 1.16

Atenolol disposition in young and elderly subjects. Br J Clin Pharmacol (1982) 1.13

Influence of age and previous use of diazepam dosage required for endoscopy. Can Med Assoc J (1978) 1.09

Intravenous administration of diazepam in patients with chronic liver disease. Gut (1976) 1.08

Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease. Br Med J (1977) 1.06

Lignocaine kinetics in cardiac patients and aged subjects. Br J Clin Pharmacol (1977) 1.04

Pharmacokinetics of ketoprofen in the elderly. Br J Clin Pharmacol (1983) 1.00

Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut (1986) 0.99

Altered elimination of desmethyldiazepam in the elderly. Br J Clin Pharmacol (1979) 0.99

Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam. Br J Clin Pharmacol (1983) 0.98

Diurnal variations in plasma diazepam concentrations associated with reciprocal changes in free fraction. Br J Clin Pharmacol (1980) 0.98

Determinants of hepatic function in liver cirrhosis in the rat. Multivariate analysis. J Clin Invest (1988) 0.94

Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. Br J Clin Pharmacol (1982) 0.93

Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction. Br J Clin Pharmacol (1998) 0.90

Pharmacokinetics in the elderly. Environ Health Perspect (1994) 0.90

Prescribing of psychoactive drugs for chronically ill elderly patients. Can Med Assoc J (1978) 0.90

Sedation for gastroscopy: a comparative study of midazolam and Diazemuls in patients with and without cirrhosis. Br J Clin Pharmacol (1986) 0.88

The influence of age and smoking on the elimination of disopyramide. Br J Clin Pharmacol (1985) 0.87

Responsiveness to oral diazepam in the elderly: relationship to total and free plasma concentrations. Br J Clin Pharmacol (1985) 0.87

Plasma concentrations of diazepam and desmethyldiazepam during chronic diazepam therapy. Br J Clin Pharmacol (1978) 0.86

Clearance (née Rowland) concepts: a downdate and an update. J Pharmacokinet Pharmacodyn (2010) 0.85

Plasma protein binding of frusemide in liver disease: effect of hypoalbuminaemia and hyperbilirubinaemia. Br J Clin Pharmacol (1989) 0.85

Single dose pharmacokinetics and pharmacodynamics of oral loprazolam in the elderly. Br J Clin Pharmacol (1985) 0.85

Food intake and plasma binding of diazepam. Br J Clin Pharmacol (1977) 0.83

Pharmacokinetics of brotizolam in the elderly. Br J Clin Pharmacol (1983) 0.82

Diazepam/beta-adrenoceptor antagonist interactions. Br J Clin Pharmacol (1984) 0.82

Valproic acid and diazepam interaction in vivo. Br J Clin Pharmacol (1982) 0.81

The effect of age on the pharmacokinetics of ifosfamide. Br J Clin Pharmacol (1990) 0.79

Pharmacokinetics of isoniazid in the elderly. Br J Clin Pharmacol (1980) 0.79

Serum protein binding of diazepam in maternal and foetal serum during pregnancy. Br J Clin Pharmacol (1982) 0.78

Pharmacokinetics of drugs in the elderly. J R Soc Med (1994) 0.78

The use of benzodiazepines in clinical practice. Br J Clin Pharmacol (1981) 0.78

Altered elimination of antipyrine in patients with acute viral hepatitis. Gut (1976) 0.78

Liver grafts from selected older donors do not have significantly more ischaemia reperfusion injury. HPB (Oxford) (2011) 0.77

The pharmacokinetics of midazolam following orthotopic liver transplantation. Br J Clin Pharmacol (1989) 0.77

ABC of poisoning. The elderly. Br Med J (Clin Res Ed) (1984) 0.77

Nizatidine (300 mg nocte) does not interfere with diazepam pharmacokinetics in man. Br J Clin Pharmacol (1987) 0.76

Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome. Drugs Context (2015) 0.75

Production of rheumatoid factor in adoptively immune guinea-pigs after challenge with Treponema pallidum. Immunology (1992) 0.75

Direct measurement of chlormethiazole extraction by liver, lung and kidney in man. Br J Clin Pharmacol (1981) 0.75

Psychopharmacology in medical practice--the benefits and the risks. West J Med (1981) 0.75

Social drinking and drugs. Br Med J (Clin Res Ed) (1981) 0.75

Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers. CPT Pharmacometrics Syst Pharmacol (2016) 0.75

Factors influencing the activity and fate of benzodiazepines in the body. Br J Clin Pharmacol (1981) 0.75

p16(INK4a) , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects. CPT Pharmacometrics Syst Pharmacol (2016) 0.75

Comparative effects of indomethacin on hepatic enzymes and histology and on serum indices of liver and kidney function in the rat. Br J Exp Pathol (1985) 0.75

Pharmacokinetics of oral brotizolam in patients with liver cirrhosis. Br J Clin Pharmacol (1983) 0.75

Effects of liver disease and of aging on the disposition and elimination of sedatives. Trans Am Clin Climatol Assoc (1978) 0.75

Single dose pharmacokinetics and pharmacodynamics of oral oxazepam in very elderly institutionalised subjects. Br J Clin Pharmacol (1991) 0.75

Effect of age and sex on human drug metabolism. Br Med J (1971) 5.19

Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. J Pharm Sci (1968) 4.58

Blood level distribution patterns of diazepam and its major metabolite in man. J Pharm Sci (1966) 3.60

Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet (1968) 3.10

Pharmacological and clinical studies on Valium (T.M.) a new psychotherapeutic agent of the benzodiazepine class. Curr Ther Res Clin Exp (1961) 2.55

The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther (1973) 2.54

Pharmacodynamics of carbenicillin in hepatic and renal failure. Ann Intern Med (1970) 2.47

Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur J Clin Pharmacol (1972) 2.32

Determinants of serum antipyrine half-lives in patients with liver disease. Gut (1973) 2.19

Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm (1973) 2.16

Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med (1973) 2.11

VARIATION IN THE ACTIVITY OF LIVER MICROSOMAL DRUG-METABOLIZING ENZYMES IN RATS IN RELATION TO THE AGE. Biochem Pharmacol (1964) 2.07

Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations. J Pharm Sci (1973) 2.01

Concept of a volume of distribution and possible errors in evaluation of this parameter. J Pharm Sci (1968) 1.82

Metabolism of diazepam in rat, dog, and man. J Pharmacol Exp Ther (1965) 1.69

Persistence of antibiotics in blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis. J Clin Invest (1959) 1.68

Determination of medazepam (nobrium), diazepam(valium) and their major biotransformation products in blod and urine by electron capture s-liquid chromatography. Anal Chem (1970) 1.68

Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut (1972) 1.57

Effects of change in elimination on varous parameters of the two-compartment open model. J Pharm Sci (1972) 1.51

Metabolism of amylobarbitone in patients with chronic liver disease. Br J Pharmacol (1972) 1.50

Diazepam metabolism during chronic medication unbound fraction in plasma, erythrocytes and urine. J Chromatogr (1973) 1.31

Pharmacokinetics of diazepam in dogs, mice and humans. Acta Pharmacol Toxicol (Copenh) (1971) 1.24

Metabolism of drugs in old rats. II. Metabolism in vivo and effect of drugs in old rats. Jpn J Pharmacol (1968) 1.23

The effect of cirrhosis on the disposition and elimination of meperidine in man. Clin Pharmacol Ther (1974) 1.22

Diazepam elimination in premature and full term infants, and children. J Perinat Med (1973) 1.15

Rate of aminopyrine disappearance from plasma in young and aged humans. Pharmacology (1972) 1.13

THE EFFECT OF INCREASING AGE ON THE DISTRIBUTION OF PERIPHERAL BLOOD FLOW IN MAN. J Am Geriatr Soc (1965) 1.07

Time integral of drug concentration in the central (plasma) compartment. J Pharm Sci (1970) 1.07

PHARMACOLOGIC ASPECTS OF AGING: A SURVEY OF THE EFFECT OF INCREASING AGE ON DRUG ACTIVITY IN ADULTS. J Am Geriatr Soc (1964) 1.02

Determination of bioavailability of diazepam in various formulations from steady state plasma concentration data. Clin Pharmacol Ther (1972) 1.01

DISAPPEARANCE RATE OF TOLBUTAMIDE IN NORMAL SUBJECTS AND IN DIABETES MELLITUS, LIVER CIRRHOSIS, AND RENAL DISEASE. Diabetes (1964) 0.98

The disposition of propranolol. 8. General implications of the effects of liver blood flow on elimination from the perfused rat liver. Drug Metab Dispos (1974) 0.96

Pharmacodynamic consequences of aging and their implications in the treatment of the elderly patient. Med Ann Dist Columbia (1967) 0.93

Pharmacokinetics of distribution and metabolism of ataractic drugs and an evaluation of the site of antianxiety activity. Ann N Y Acad Sci (1971) 0.93

Further studies on species difference in diazepam metabolism. Eur J Pharmacol (1970) 0.90

Clinical and electroencephalographic assessment of diazepam in liver disease. Br Med J (1971) 0.89

Metabolism of diazepam in vitro. Biochem Pharmacol (1968) 0.88

The metabolism of diazepam by liver microsomal enzymes of rats and mice. Eur J Pharmacol (1969) 0.87

Microsomal pentobarbital hydroxylase activity in acute viral hepatitis. Proc Soc Exp Biol Med (1972) 0.87

Species difference in diazepam metabolism and anticonvulsant effect. Eur J Pharmacol (1968) 0.85

Effect of experimental hepatic injury on the clearance of phenobarbital and paraldehyde. Gastroenterology (1973) 0.84

Correlation between the duration of the anticonvulsant activity of diazepam and its physiological disposition in mice. Biochem Pharmacol (1970) 0.84

Metabolism of diazepam in isolated perfused liver of rat and mouse. J Pharm Pharmacol (1968) 0.84

Influence of acute and chronic nicotine administration on EEG reactivity to drugs in rabbits. 2. Psychoactive agents. Res Commun Chem Pathol Pharmacol (1970) 0.83

Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther (1975) 7.96

Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med (1981) 3.98

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem (1994) 3.75

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest (1998) 3.66

Delayed clearance of diazepam due to cimetidine. N Engl J Med (1980) 3.45

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol (1994) 3.05

Midazolam kinetics. Clin Pharmacol Ther (1981) 2.88

Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther (2001) 2.79

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther (1985) 2.69

Telomere length in different tissues of elderly patients. Mech Ageing Dev (2000) 2.45

In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol (1998) 2.45

Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med (1980) 2.39

Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med (1989) 2.29

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (1999) 2.24

Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther (1984) 2.19

OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos (1999) 2.02

Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation (1999) 2.01

Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem (1985) 1.97

Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos (2000) 1.87

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther (1996) 1.85

Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. J Clin Invest (1974) 1.74

Affinity chromatographic isolation of the periplasmic maltose binding protein of Escherichia coli. FEBS Lett (1978) 1.71

Pharmacokinetics of ketanserin in man. Eur J Clin Pharmacol (1983) 1.69

Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med (1976) 1.68

Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther (1979) 1.62

Cimetidine impairs elimination of chlordiazepoxide (Librium) in man. Ann Intern Med (1980) 1.61

Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol (1978) 1.60

Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol (2001) 1.59

Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol (2001) 1.57

Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther (1979) 1.55

Acute hepatic necrosis with stupor or coma. An analysis of thirty-one patients. Medicine (Baltimore) (1969) 1.55

Physiologic and temporal variation in hepatic elimination of midazolam. Clin Pharmacol Ther (1982) 1.53

Amylase--its clinical significance: a review of the literature. Medicine (Baltimore) (1976) 1.51

The liver in congestive heart failure: a review. Am J Med Sci (1973) 1.50

Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium). Gastroenterology (1978) 1.48

Gastric varices secondary to splenic vein occlusion: radiographic diagnosis and clinical significance. Radiology (1979) 1.43

Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med (1982) 1.43

Acyclovir transport by the human placenta. J Lab Clin Med (1992) 1.42

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. Clin Pharmacol Ther (2000) 1.42

Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet (1985) 1.41

Impaired elimination of caffeine by oral contraceptive steroids. J Lab Clin Med (1980) 1.41

Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther (1978) 1.39

Tripotassium dicitrato bismuthate: absorption and urinary excretion of bismuth in patients with normal and impaired renal function. Aliment Pharmacol Ther (1991) 1.39

Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharmacol Exp Ther (1985) 1.38

Comparison of the pharmacokinetics of diazepam after single and subchronic doses. Eur J Clin Pharmacol (1976) 1.36

Possible interaction of fluoroquinolones with the benzodiazepine-GABAA-receptor complex. Br J Clin Pharmacol (1990) 1.35

Biological determinants of propranolol disposition in man. Clin Pharmacol Ther (1978) 1.35

Altered hepatic blood flow and drug disposition. Clin Pharmacokinet (1976) 1.34

Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther (1978) 1.33

Cholangitis with a silver lining. Arch Surg (1979) 1.33

Cimetidine spares the glucuronidation of lorazepam and oxazepam. Gastroenterology (1980) 1.33

Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics (1999) 1.33

Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther (1999) 1.32

Fatty liver: biochemical and clinical considerations. Am J Dig Dis (1975) 1.30

Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. Biochemistry (1984) 1.29

The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration. Clin Pharmacokinet (1979) 1.28

Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J Pharmacol Exp Ther (1976) 1.28

Studies on the intracerebral toxicity of ammonia. J Clin Invest (1967) 1.27

Clearance approaches in pharmacology. Pharmacol Rev (1987) 1.27

Pathogenesis of hepatic encephalopathy--with special reference to the role of ammonia. Am J Clin Nutr (1970) 1.27

Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter (1998) 1.27

Inhibition of microsomal drug metabolism by histamine H2-receptor antagonists studied in vivo and in vitro in rodents. Gastroenterology (1982) 1.27

Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. Eur J Clin Pharmacol (1980) 1.26

Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J Pharmacol Exp Ther (1987) 1.25

Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet (1994) 1.25

Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin Pharmacol Ther (1984) 1.25

Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation (1987) 1.22

Normal metabolism of morphine in cirrhosis. Gastroenterology (1981) 1.22

The effect of cirrhosis on the disposition and elimination of meperidine in man. Clin Pharmacol Ther (1974) 1.22

A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther (1998) 1.21

Erythrocyte uptake and plasma binding of diphenylhydantoin. Clin Pharmacol Ther (1974) 1.21

A prospective study to determine the efficacy of antibiotics in acute pancreatitis. Ann Surg (1976) 1.20

Cimetidine/diazepam interaction. Lancet (1979) 1.19

In utero ethanol exposure causes mitochondrial dysfunction, which can result in apoptotic cell death in fetal brain: a potential role for 4-hydroxynonenal. Alcohol Clin Exp Res (2001) 1.18

Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet (1992) 1.17

Disposition of chlordiazepoxide: sex differences and effects of oral contraceptives. Clin Pharmacol Ther (1979) 1.16

Cimetidine increases steady state plasma levels of propranolol. Br J Clin Pharmacol (1981) 1.16

Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation. Br J Clin Pharmacol (1986) 1.14

Pharmacodynamic interaction between midazolam and a specific benzodiazepine antagonist in humans. J Clin Pharmacol (1985) 1.14

Drug disposition and liver disease. Drug Metab Rev (1975) 1.14

P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res (1999) 1.14

Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer (1996) 1.13

Induction of propranolol metabolism by rifampicin. Br J Clin Pharmacol (1983) 1.13

Hepatic encephalopathy. Gastroenterology (1979) 1.13

Bacteremia with upper gastrointestinal endoscopy. Ann Intern Med (1975) 1.13

Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol (1990) 1.13

Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination. J Lab Clin Med (1977) 1.13

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics (2001) 1.12